viewFeedback PLC

Feedback surges on potential collaboration with Alliance Medical

The company are investigating plans to integrate the TexRAD software into Alliance's lung cancer service across its imaging network.

'We anticipate this will enhance lung cancer diagnosis and prognosis within the NHS,' said Alliance's Charles Niehaus

Feedback (LON:FDBK) shares surged as the medical imaging software company, revealed it is discussing hooking up with imaging services leader Alliance Medical Group.

The intention is to integrate Feedback's TexRAD texture analysis software into Alliance's lung cancer imaging service. 

Although the technical discussions are at a very early stage, this is considered by Feedback to be potentially of great significance as regards the future commercialisation of TexRAD software.

Alliance and Feedback plan to undertake a multi-centre imaging research study to assess the use of TexRAD in lung cancer, with the eventual aim of gaining National Institute for Health and Care Excellence approval for TexRAD to be used in the lung cancer pathway..

“The planned research study in lung cancer will be an important step towards the future commercialisation of TexRAD," said Dr Balaji Ganeshan, chief executive of TexRAD and director of New Business at Feedback.

Quick facts: Feedback PLC

Price: 1.05 GBX

Market: LSE
Market Cap: £11.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Feedback PLC named herein, including the promotion by the Company of Feedback PLC in any Content on the Site, the Company receives from said...



'Undoubtedly an exciting time for Texrad' says Feedback plc Chairman

Feedback plc (LON:FDBK) chairman Alastair Riddell caught up with Proactive's Andrew Scott to discuss their latest results and outlook for the company. They’re a leader in medical image processing and analysis with their lead product Texrad - a software instrument for analysing medical...

on 11/17/2016

2 min read